Publication Name	World Journal of Gastroenterology
Manuscript ID	80237
Country	Argentina

Received	2022-09-22 01:08
Peer-Review Started	2022-09-22 01:10
To Make the First Decision
Return for Revision	2022-10-18 19:11
Revised	2022-10-26 16:29
Second Decision	2022-11-24 03:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-11-27 17:37
Articles in Press	2022-11-27 17:37
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-11-21 21:03
Typeset the Manuscript	2022-11-28 06:13
Publish the Manuscript Online	2022-12-19 10:48

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Domingo Balderramo
ORCID	Author(s) ORCID Number Domingo Balderramo http://orcid.org/0000-0001-9598-2577
Funding Agency and Grant Number
Corresponding Author	Domingo Balderramo, MD, PhD, Professor, Hospital Privado Universitario de Córdoba, Instituto Universitario de Ciencias Biomédicas de Córdoba, Naciones Unidas 346, Cordoba 5016, Argentina. dbalderramo@hospitalprivadosa.com.ar
Key Words	Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Dual-therapy biologic therapy; Small molecule drugs; Clinical remission
Core Tip	Patients with inflammatory bowel disease (IBD) require prolonged treatment and high utilization of healthcare resources. About 40% of patients are refractory to different treatments with an increase need for hospitalization and surgery. Dual therapy, a strategy applicable to refractory IBD patients, includes the combination of two biologics or a biologic in combination with a small molecule drug. There are two distinct scenarios in IBD therapy in which this approach can be used: (1) refractory active luminal disease without extraintestinal manifestations; and (2) patients with IBD in remission, but with active extraintestinal manifestations or immune-mediated inflammatory diseases.
Publish Date	2022-12-19 10:48
Citation	Balderramo D. Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease. World J Gastroenterol 2022; 28(47): 6743-6751
URL	https://www.wjgnet.com/1007-9327/full/v28/i47/6743.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i47.6743

Full Article (PDF)	WJG-28-6743.pdf
Full Article (Word)	WJG-28-6743.docx
Manuscript File	80237_Auto_Edited-LM.docx
Answering Reviewers	80237-Answering reviewers.pdf
Audio Core Tip	80237-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	80237-Conflict-of-interest statement.pdf
Copyright License Agreement	80237-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	80237-Language certificate.pdf
Peer-review Report	80237-Peer-review(s).pdf
Scientific Editor Work List	80237-Scientific editor work list.pdf